Otsuka Pharmaceutical Company, Limited

Chikamasa Yamashita

Akitsuna Akagi

Yuichiro Fukunaga

Shigeru Ibaragi

Masaaki Odomi

Hitoshi Matsushita

Muneyoshi Ishikawa

Gohachiro Miyamoto

Kouzo Ishida

A dry powder inhalation system suitable for transpulmonary administration characterized by using a combination of:

Dry powder inhalation system for transpulmonary administration

The present invention provides a novel dry powder inhalation system suitable for transpulmonary administration. The dry powder inhalation system of the invention characterized by using a combination of:

The present invention aims to provide a freeze-dried preparation in which the influenza vaccine exhibits improved stability. A freeze-dried preparation in which the influenza vaccine exhibits significantly improved stability can be obtained by freeze-drying an aqueous solution that meets the following conditions (A) to (C):

Lyophilized preparation comprising influenza vaccine, and method for preparation thereof

A dry powder inhalation system suitable for transpulmonary administration. The dry powder inhalation system is characterized by using a combination of:

An inhalation device for transpulmonary administration comprises: a chamber () for containing a pharmaceutical composition which is pulverized into fine particles by an air-generated impact for dispersal in air; an air inlet flow path () for introducing to the chamber () outside air to apply the air-generated impact to the pharmaceutical composition and for injecting the outside air toward the pharmaceutical composition; an inhalation flow path () for inhaling the pulverized pharmaceutical composition; a housing () for accommodating the chamber (), the air inlet flow path (), and the inhalation flow path (); a mouthpiece () provided at one end of the housing (), the mouthpiece () being provided with a mouth-side flow path () which communicates with the inhalation flow path (), and an auxiliary flow path ().

Inhalation device for transpulmonary administration

A non-powder-form freeze-dried composition for transpulmonary administration has a disintegration index greater than or equal to 0.015 and contains at least one active ingredient. The composition becomes fine particles upon receiving air impact at an air speed greater than or equal to 1 meter/second and an air flow rate greater than or equal to 17 milliliters/second. The fine particles have a mean particle diameter less than or equal to 1&#xd7;10meters and/or a fine particle fraction greater than or equal to 10%. A method of making the composition, a vessel containing the composition, a method of administering the composition, a dry powder inhalation system for transpulmonary administration, and a method of transpulmonary administration are also disclosed.

Composition, vessel, dry powder inhalation system, and related methods for transpulmonary administration

Provisions of a foam inhibitor which effectively inhibits foaming (bubbling) caused at the time of dissolving dry compositions and of a water-soluble dry composition which comprises the foam inhibitor. The form inhibitor is suitable for inhibiting foaming caused at the time of dissolving dry compositions comprising saccharide which contain a hydrophobic amino acid as essential ingredient; and the water-soluble dry composition contains pharmacologically active proteinaceous substance, saccharide and hydrophobic amino acid having the hydropathy index of about not less than 2, wherein the concentration of the hydrophobic amino acid is in the range of 0.05 wt. % to less than 40 wt. % based on the total amount of the dry composition.

Water-soluble dry compositions

Water soluble dry compositions

A pharmaceutical composition for suppository which comprises buprenorphine or its pharmaceutically acceptable acid addition salt as the active ingredient and a mixed base composed of 70 to 95 wt. % of polyethylene glycol with average molecular weight of 200 to 20,000 and 30 to 5 wt. % of propylene glycol.

Growing community of inventors

Naruto, Japan

Chikamasa Yamashita